23S rRNA mutation A2074C conferring high-level macrolide resistance and fitness cost in Campylobacter jejuni

Microb Drug Resist. 2009 Dec;15(4):239-44. doi: 10.1089/mdr.2009.0008.

Abstract

To examine the development of macrolide resistance in Campylobacter jejuni and assess the fitness of the macrolide-resistant mutants, two macrolide-susceptible C. jejuni strains, American Type Culture Collection (ATCC) 33291 and H1, from different geographic areas were exposed to tylosin in vitro. Multiple mutant strains were obtained from the selection. Most of the high-level macrolide-resistant strains derived from the selection exhibited the A2074C transversion in all three copies of 23S rRNA and displayed strong stability in the absence of antibiotic selection pressure. The competition experiments demonstrated that the strains containing the A2074C transversion imposed a fitness cost in competition mixtures. In addition, the fitness cost of the mutation was not ameliorated after approximately 500 generations of evolution under laboratory conditions. These findings indicate that the A2074C transversion in C. jejuni is not only correlated with stable and high-level macrolide resistance but also associated with a fitness cost.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Campylobacter jejuni / drug effects*
  • Campylobacter jejuni / genetics
  • Drug Resistance, Bacterial / genetics*
  • Erythromycin / pharmacology
  • Macrolides / pharmacology*
  • Microbial Sensitivity Tests
  • Mutation
  • RNA, Bacterial / genetics
  • RNA, Ribosomal, 23S / genetics
  • Tylosin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • RNA, Bacterial
  • RNA, Ribosomal, 23S
  • Erythromycin
  • Tylosin